ARQTArcutis Biotherapeutics, Inc.
What is the market doing?
No clear lean: in an uptrend, but heavily shorted (+14% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +5% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ARQT is trading
Arcutis Biotherapeutics, Inc. is +53% over the past year while the S&P 500 is +18%: 35 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +5.1%
vs 200-day average · close to trend
- RSI (14)
- 53
RSI (14) · neutral
- Below its 52-week high
- 15%
Below its 52-week high
Details›
- Last close2026-10-09
- $26.56
- 1 monthS&P 500 +2.7%
- +14%
- 1 yearS&P 500 +18%
- +53%
- 5 yearsS&P 500 +88%
- +25%
- vs 50-day average$25.48
- +4.2%
- 52-week high
- $31.20
- 52-week low
- $16.73
- Annualised volatility
- 61%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$1.4M
| Year | Return |
|---|---|
| 2026 (year to date) | −8.5% |
| 2025 | +108% |
| 2024 | +331% |
| 2023 | −78% |
| 2022 | −29% |
| 2021 | −26% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | +7.7% |
| Feb | 7 | 6 of 7 | +21% |
| Mar | 7 | 3 of 7 | −4.1% |
| Apr | 7 | 3 of 7 | +3.4% |
| May | 7 | 3 of 7 | −10% |
| Jun | 7 | 6 of 7 | +9.4% |
| Jul | 7 | 5 of 7 | +3.0% |
| Aug | 7 | 3 of 7 | −3.9% |
| Sep | 7 | 4 of 7 | −2.9% |
| Oct | 7 | 2 of 7 | −13% |
| Nov | 6 | 3 of 6 | +15% |
| Dec | 6 | 4 of 6 | +15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.